

## **Webcast Alert: Isis Pharmaceuticals Hosts Dr. Klaus Parhofer to Review KYNAMRO™ Data Presented at the European Society of Cardiology Congress 2012**

August 27, 2012

CARLSBAD, Calif., Aug. 27, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

**What:** KYNAMRO™ data presented at the ESC Congress 2012

**When:** Wednesday, August 29<sup>th</sup> at 10:00 a.m. ET / 7:00 a.m. PT

**Where:** [www.isispharm.com](http://www.isispharm.com)

**How:** Live on the Internet. Simply log onto our Web site listed above.

**Contacts:** D. Wade Walke, Ph.D.  
Executive Director, Corporate Communications and Investor Relations  
(760) 603-2741

Amy Blackley, Ph.D.  
Associate Director, Corporate Communications  
(760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at [www.isispharm.com](http://www.isispharm.com).

### **ABOUT ISIS PHARMACEUTICALS, INC.**

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at [www.isispharm.com](http://www.isispharm.com).

### **Forward-Looking Statements**

This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.